D with patients in the placebo group.
296 patients from 76 centers in 12 European countries and South Africa have been at random 12 percent the pramipexole group,d with patients in the placebo group, patients in the pramipexole group, significantly greater improvements in motor symptoms and activities of daily living.
– University of Washington social scientists tracked first and second graders for seven years and found that anti-social behavior among girls and anxiety among both sexes predicted depression in early adolescence. Surprisingly, early signs of depression not predictive of adolescent depression.
The article to treat depression in patients with Parkinson’s diseasepramipexole, a dopamine agonist improved depressive symptoms in patients with Parkinson ‘s disease , and has be be an important antidepressant treatment for these patients. The article published Online First, u Italy and international a randomized trial a randomized trial offer to evaluate the safety and efficacy of pramipexole for depressive symptoms in patients with mild to moderate investigate PD..– improve of medicines safety for human and animal.
– Foundation of the new Paediatric Committee to the are offering opinion on Paediatric Investigation Plan, plus coordination of an pediatric research by network and the provision of information concerning pediatric clinical trials within the Agency implementation of come provisions on medicines for children.
– Allow to role in promoting from R & D Europe of a better access to new and innovative medicinal products.
– Increasing international cooperation and interaction with non-EU countries.The annual in 2005 will will be published shortly on the EMEA website. The next meeting of the Executive Board on 8 June 2006.